Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: Assessing impact of poor accrual on premature trial closure requires a relevant metric. We propose defining accrual sufficiency on apparent ability to address primary endpoints (PE) rather than attaining accrual targets. Experimental Design: All phase III trials open January 1, 1993, to December 31, 2002, by five U.S. oncology Clinical Trials Cooperative Groups (CTCG) were evaluated for accrual sufficiency and scientific results. Sufficient accrual included meeting accrual target, CTCGs documentation attesting adequate accrual, or conclusive results at interim analysis; insufficient accrual included poor accrual as cited closure reason or other reasons rendering a trial unable to address its primary endpoints. Closure rates based on our accrual sufficiency definition are compared with rates of meeting accrual targets and addressing the primary endpoints. A percentage of target accrual above which trials commonly answer the intended scientific question was identified to serve as an alternative to meeting full target accrual in designating accrual success. Results: Of 238 eligible trials, 158 (66%) closed with sufficient accrual. Among 80 trials with insufficient accrual, 70 (29%) closed specifically because of poor accrual. Inadequate accrual rates are overemphasized when defining accrual success solely by meeting accrual targets. Nearly 75% of trials conclusively addressed the primary endpoints with positive results in 39% of trials. Exceeding 80% of target accrual serves as a reliable proxy for answering the intended scientific question. Conclusions: Approximately one third of phase III trials closed with insufficient accrual to address the primary endpoints, primarily due to poor accrual. Defining accrual sufficiency broader than meeting accrual targets represents a fairer account of trial closures. Clin Cancer Res; 18(1); 256–62. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, A. M., Knight, R. C., Campbell, M. K., Entwistle, V. A., Grant, A. M., Cook, J. A., Elbourne, D. R., Francis, D., Garcia, J., Roberts, I., et al. (2006) · Trials · doi:10.1186/1745-6215-7-9 · Cited by 946
Boutron, I. (2010) · JAMA · doi:10.1001/jama.2010.651 · Cited by 842 · cited 1×
“Deflecting focus from the primary results has been identified in trial publications with statistically inconclusive results (11).”
Ioannidis, J. P. A. (1998) · JAMA · doi:10.1001/jama.279.4.281 · Cited by 632 · cited 2×
“Resulted in principal publication 172 (79) 135 (81) 37 (73) Answered intended scientific question 159 (73) 125 (75) 34 (67) Positive results 62 (39) 52 (42) 10 (29) Negative results 97 (61) 73 (58) 24 (71) Inconclusive 13 (6) 10 (6) 3 (6) Closed 7 years without a principal publication 46 (21) 32 (19) 14 (27)”
BackgroundFactors that limit the quality, number and progress of randomised controlled trials
Prescott, Counsell, Gillespie, Grant, Russell, Kiauka, Colthart, Ross, Shepherd, & Russell (1999) · Health Technology Assessment · doi:10.3310/hta3200 · Cited by 390 · cited 1×
“Finally, prior work suggests there are certain trial design factors that reduce the likelihood of attaining sufficient accrual (15, 16).”
BackgroundOutcome Reporting Among Drug Trials Registered in ClinicalTrials.gov
Bourgeois, F. T., Murthy, S., & Mandl, K. D. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00006 · Cited by 332
Time to publication for results of clinical trials
Hopewell, S., Clarke, M. J., Stewart, L., & Tierney, J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000011.pub2 · Cited by 243 · cited 3×
“Sufficient accrual 158 (66) 121 (67) 37 (65) Documented closure with complete accrual 134 (56) 101 (56) 33 (58) Closed at interim analysis with positive results 9 (4) 8 (4) 1 (2) Closed at interim analysis with negative results 12 (5) 10 (6) 2 (3) Closed because of toxicity 3 (1) 2 (1) 1 (2) Insufficient accrual 80 (3…”
Background
Cited by
Carlisle, B., Kimmelman, J., Ramsay, T., & MacKinnon, N. (2015) · Clinical Trials · doi:10.1177/1740774514558307 · Cited by 367
Adult cancer clinical trials that fail to complete: an epidemic?
Stensland, K. D., McBride, R. B., Latif, A., Wisnivesky, J., Hendricks, R., Roper, N., Boffetta, P., Hall, S. J., Oh, W. K., & Galsky, M. D. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju229 · Cited by 161
Bentley, C., Cressman, S., van der Hoek, K., Arts, K., Dancey, J., & Peacock, S. (2019) · Clinical Trials · doi:10.1177/1740774518820060 · Cited by 104
Predicting Low Accrual in the National Cancer Institute’s Cooperative Group Clinical Trials
Bennette, C. S., Ramsey, S. D., McDermott, C. L., Carlson, J. J., Basu, A., & Veenstra, D. L. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv324 · Cited by 108
Metadata
- Authors
- Schroen, A. T., Petroni, G. R., Wang, H., Thielen, M. J., Gray, R., Benedetti, J., Wang, X. F., Sargent, D. J., Wickerham, D. L., Cronin, W., Djulbegovic, B., & Slingluff, C. L.
- Venue
- Clinical Cancer Research
- Published
- 2012-01-01
- Volume
- 18
- Issue
- 1
- Pages
- 256-262
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2128034114
- Cited by
- 73
- References
- 6
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-1633
- The paper
- Schroen, A. T., Petroni, G. R., Wang, H., Thielen, M. J., Gray, R., Benedetti, J., Wang, X. F., Sargent, D. J., Wickerham, D. L., Cronin, W., Djulbegovic, B., & Slingluff, C. L. (2012). Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-1633
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.